In:
Biomarkers in Medicine, Future Medicine Ltd, Vol. 15, No. 6 ( 2021-04), p. 437-454
Abstract:
Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The ‘omics’ era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.
Type of Medium:
Online Resource
ISSN:
1752-0363
,
1752-0371
DOI:
10.2217/bmm-2020-0691
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2021
